IMR Press / FBL / Volume 18 / Issue 1 / DOI: 10.2741/4092

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Review

Integrating leptin and cAMP pathways in triple-negative breast cancer cells

Show Less
1 Department of Biochemistry and Biophysics, Second University of Naples, Medical School, Via L. De Crecchio 7, 80138 Naples, Italy
Academic Editor:Adriana De Siervi
Front. Biosci. (Landmark Ed) 2013, 18(1), 133–144; https://doi.org/10.2741/4092
Published: 1 January 2013
(This article belongs to the Special Issue BRCA1 and BRCA2 role in cancer)
Abstract

Triple-negative breast cancers are characterised by an aggressive phenotype, are often found in younger women and have been associated with poor prognosis. Because triple-negative breast cancer patients are unresponsive to current targeted therapies and other treatment options are only partially effective, new pharmacological approaches are warranted. The obesitylinked adipokine, leptin, is a well known mitogen/survival factor in breast cancer cells and several studies have addressed its role in breast cancer. Surprisingly, recent in vitro studies have shown that leptin enhances the anti- proliferative effects of cAMP elevation in triple-negative breast cancer cells by apoptosis induction. In the current review, we discuss on the role of cAMP as a growth suppressor and of leptin as a growth promoting factor in breast cancer cells and we will focus on the molecular pathways involved in the antiproliferative interaction between leptin and cAMP elevation. The rationale for the possible development of a simple, cheap and innovative approach for therapeutic intervention in triple-negative breast cancer, based on the use of cAMP elevating drugs at tolerable doses, will be discussed.

Keywords
Breast Cancer
STAT3
Novel Anticancer Therapy
cAMP elevating agents
SOCS3
Share
Back to top